结合疫苗市场：按产品类型、适应症、病原体类型、患者类型和地区划分

预计到2026年，结合疫苗市场规模将达到259.66亿美元，到2033年将达到492.2亿美元。预计从2026年到2033年，其复合年增长率将达到9.6%。

结合疫苗将弱抗原与强抗原结合，使免疫系统对弱抗原产生更强的反应，从而提供主动免疫。在结合疫苗中，弱抗原与强抗原共用结合，引发针对弱抗原的更强免疫反应。弱抗原是一种与强蛋白抗原结合的多醣体。

结合疫苗针对多种导致疫苗可预防死亡的主要原因疾病。结合疫苗的优点包括诱导免疫记忆和减少细菌无症状携带，从而显着提高群体免疫力。这些疫苗可提供针对不同细菌菌株的免疫力。例如，根据美国疾病管制与预防中心 (CDC) 2019 年 4 月的数据，截至 2022 年 1 月 24 日，肺炎链球菌结合疫苗（PCV13）可预防 13 种肺炎链球菌菌株感染。同时，美国食品药物管理局(FDA) 于 2021 年核准了PCV15 和 PCV20 用于 18 岁及以上成人。临床试验数据显示，PCV15 和 PCV20 与 PCV13 一样，能够刺激人体免疫系统产生抗体，帮助抵抗肺炎链球菌。

市场动态

在预测期内，肺炎病例的增加预计将推动全球结合疫苗市场的成长。例如，2021年8月，美国国家生物技术资讯中心（NCBI）发布了一份关于「社区获得性肺炎」的报告，该报告估计全球社区获得性肺炎的发生率为每千人年1.5至14例，并指出其发病率受地区、季节和人口统计特征的影响。在美国，社区型肺炎的年发生率为每万名成年人24.8例，且发病率随年龄增加，但入住加护病房患者的死亡率高达23%。

预计各国政府加强推广新疫苗将推动全球结合疫苗市场在预测期内成长。例如，2021年10月，印度卫生部长曼舒克·曼达维亚在「自由甘露节」（Azadi ka Amrit Mahotsav）期间，启动了13价肺炎球菌结合疫苗（PCV）在全国范围内的推广接种，该疫苗是「全民免疫计画」（UIP）的一部分。同时，印度也提供了有关PCV的公共关係宣传和推广资料。

本报告的主要特点

• 本报告指出了各个细分市场的潜在商机，并概述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本文根据以下参数，介绍了全球结合疫苗市场主要企业的概况：公司概况、产品系列、主要亮点、财务绩效和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球结合疫苗市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球结合疫苗市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
• 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
• 影响分析
• 市场趋势
• 主要进展
• 产品平臺分析
• 投资和政府倡议
• GAVI PATH计划详情
• 企业合併（M&A）
• 法规环境
• 波特五力分析
• PEST分析

第四章 全球结合疫苗市场：依产品类型划分（2026-2033 年）

• 概述
• 单价结合疫苗
• 多价结合疫苗

第五章：全球结合疫苗市场：依适应症划分（2026-2033 年）

• 概述
• 肺炎球菌
• 流感
• 脑膜炎奈瑟菌
• 伤寒

第六章 全球结合疫苗市场：依病原体类型划分（2026-2033 年）

• 概述
• 细菌
• 病毒性的

第七章 全球结合疫苗市场：依病患类型划分（2026-2033 年）

• 概述
• 儿童
• 成人

第八章 全球结合疫苗市场：按地区划分（2026-2033年）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 北非
  • 中非
  • 南非

第九章 竞争情势

• 热图分析
• 公司简介
  • Sanofi SA
  • Pfizer, Inc.
  • Merck &Co., Inc.
  • GlaxoSmithKline plc.
  • Bharat Biotech
  • Serum institute of India Pvt. Ltd
  • Biological E. Limited.
  • Bio-Med
  • Biological E Limited
  • CSL Limited
  • Novartis AG
  • Vaxcyte
  • GSBPL
  • Taj Pharmaceuticals Limited.
  • Bavarian Nordic

第十章

• 参考
• 分析方法
• 关于 Coherent Market Insights

Conjugate Vaccine Market is estimated to be valued at USD 25,966 Mn in 2026 and is expected to reach USD 49,220 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study

• This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
• Disease Indication Insights (Revenue, USD Mn, 2026 - 2033)
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
• Pathogen Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Bacterial
  • Viral
• Patients Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Pediatric
  • Adults
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Sanofi S.A
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Bharat Biotech
  • Serum institute of India Pvt. Ltd.
  • Biological E. Limited
  • Bio-Med
  • Bavarian Nordic
  • CSL Limited
  • Novartis AG
  • Vaxcyte
  • GSBPL
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Pathogen Type
  • Market Snapshot, By Patient Types
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Pipeline Analysis
• Investments and Government Initiatives
• GAVI and PATH Program Details
• Merger and Acquisition
• Regulatory Scenario
• PORTER'S Five Forces
• PEST Analysis

4. Global Conjugate Vaccine Market, By Product Type, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Monovalent Conjugate Vaccine
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Multivalent Conjugate Vaccine
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Conjugate Vaccine Market, By Disease Indication, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pneumococcal
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Influenza
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Meningococcal
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Typhoid
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Conjugate Vaccine Market, By Pathogen Type, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Bacterial
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Viral
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Conjugate Vaccine Market, By Patient Type,2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Paediatric
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adult
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

8. Global Conjugate Vaccine Market, By Region, 2026-2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Sanofi S.A
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Pfizer, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • GlaxoSmithKline plc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bharat Biotech
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Serum institute of India Pvt. Ltd
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Biological E. Limited.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bio-Med
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Biological E Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • CSL Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Vaxcyte
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • GSBPL
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Taj Pharmaceuticals Limited.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bavarian Nordic
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About Us